Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CITALOPRAM HYDROBROMIDE

All products: general benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
  • Fluoxetine (Prozac): general benefit, Not a benefit
  • Fluvoxamine (Luvox): general benefit
  • Paroxetine (Paxil): general benefit, Not a benefit
  • Sertraline (Zoloft): general benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

Celexa · DIN 02239607 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Celexa (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Celexa · DIN 02239607 Manufacturer: Lundbeck Canada Inc.; listing date 2000-01-17 Health Canada: Marketed since 1999-03-08 · brand CELEXA 20 MG · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Lundbeck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1332 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077 · Verify on the e-Formulary ↗ (DIN 02239607)

Source record
DIN 02239607: Celexa Raw flags: sec3=Y Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id VLH Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $1.8776; ministry $0.1332 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239607 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077
Interchangeable products
Accel Citalopram Tablets · DIN 02355256 · $0.1332 Apo-Citalopram · DIN 02246056 · $0.1332 Auro-Citalopram · DIN 02275562 · $0.1332 CCP-Citalopram · DIN 02459914 · $0.1332 Citalopram · DIN 02353660 · $0.1332 Citalopram · DIN 02387956 · $0.1332 Citalopram · DIN 02430541 · $0.1332 Co Citalopram · DIN 02248050 · $0.1332 Jamp-Citalopram · DIN 02313405 · $0.1332 M-Citalopram · DIN 02467836 · $0.1332 Mar-Citalopram · DIN 02371898 · $0.1332 Mint-Citalopram · DIN 02429705 · $0.1332 NRA-Citalopram · DIN 02477645 · $0.1332 Natco-Citalopram · DIN 02443880 · $0.1332 PMS-Citalopram · DIN 02248010 · $0.1332 Ran-Citalo · DIN 02285622 · $0.1332 Riva-Citalopram · DIN 02303264 · $0.1332 Sandoz Citalopram · DIN 02248170 · $0.1332 Septa-Citalopram · DIN 02355272 · $0.1332 Teva-Citalopram · DIN 02293218 · $0.1332
Shortage status: resolved shortage (ended 2020-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239607
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

PAROXETINE HCL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit (16), General benefit (31) · strengths: 10mg, 20mg, 30mg · Tab

SERTRALINE HCL

· 49 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: depressive illness, the symptomatic relief of depressive illness
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: AMITRIPTYLINE, SERTRALINE HCL MIRTAZAPINE · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) 1 INDICATIONS REMERON® (mirtazapine) is indicated for: • the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00075141.PDF; date May 4, 2021; DIN 02243910; fetched 2026-09-10 Product monograph • the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00075141.PDF; date May 4, 2021; DIN 02243910; fetched 2026-09-10 Product monograph AMITRIPTYLINE · General benefit 1 INDICATIONS pms-AMITRIPTYLINE (amitriptyline hydrochloride) is indicated for: • Drug management of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00074345.PDF; date December 11, 1998; DIN 00654507; fetched 2026-09-10 Product monograph SERTRALINE HCL · General benefit 1 INDICATIONS ZOLOFT (sertraline hydrochloride capsules) is indicated for: Adults  Depression ZOLOFT is indicated for the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00072140.PDF; date AUG 22, 2023; DIN 01962779; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications CELEXA (citalopram hydrobromide) is indicated for: • the symptomatic relief of depressive illness in adults The relapse rate was significantly lower in CELEXA-treated patients than in placebo-treated patients in two placebo-controlled studies that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with CELEXA (see 14.1 Clinical Trials by Indication). Nevertheless, the physician who elects to use CELEXA for extended periods should periodically re-evaluate the long- term usefulness of the drug for the individual patient. 1.1. Pediatrics Pediatrics (<18 years of age): CELEXA is not indicated for use in patients below the age of 18 (see 7 Warnings and Precautions, Psychiatric, Potential Association with Behavioural and Emotional Changes, Including Self-Harm). 1.2. Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety and effectiveness (see 4.2 Recommended Dose and Dosage Adjustment, Geriatrics and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00082636.PDF PM date: not printed or not captured Source product: CELEXA 20 MG; DIN 02239607; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.